Publication | Closed Access

Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial

Tissue EngineeringPercutaneous Coronary InterventionCardiovascular DiseaseFirst-in-man TrialAtherosclerosisMyocardial InfarctionPharmacologyMedicineCardiologyCoronary Artery DiseaseAcute Myocardial InfarctionMonth Results